• Yang Cai, Yu-Gang Jiang, Ming Wang, Zhuo-Hang Jiang, and Zhi-Gang Tan.
• Department of Neurosurgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
• Medicine (Baltimore). 2020 Sep 18; 99 (38): e22238.

BackgroundSystematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma.MethodsElectronic databases including PubMed, MEDLINE, EMBASE, Cochrane Library Central Register of Controlled Trials, WanFang, and China National Knowledge Infrastructure (CNKI) were used to search for studies related to the utilization of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma. Literature screening, extraction of data, and evaluation of high standard studies were conducted by 2 independent researchers. The robustness and strength of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic methodology for recurrent high-grade glioma was assessed based on the odds ratio (OR), mean differences (MDs), and 95% confidence interval (CI). RevMan 5.3 software was used for carrying out the statistical analysis.ResultsThese results obtained in this study will be published in a peer-reviewed journal.ConclusionEvidently, the conclusion of this study will provide an assessment on whether combined procarbazine, lomustine, and vincristine provides an effective and safe form of treatment for recurrent high-grade glioma.Systematic Review Registration NumberINPLASY202080078.

29 keywords...

hide…